NIH awards $102.5M for Antibacterial Resistance Research, Dx development

The national institutes of health has renewed funding for the Antibacterial Resistance Leadership (ARLG) with up to $102.5 million over seven years.

The grant starts with $15 million in 2020, awarded by the National Institute for Allergy and Infectious Disease (NIAID) to coprincipal investigators Vance Fowler of Duke University and Henry Chambers of the University of California, San Francisco.

As part of the new grant, ARLG will “support improved diagnostic tests for identifying antibiotic-resistant microbes,” NIH said in a statement. ARLG will also work on developing non-antibiotic approaches to fighting those organisms, including vaccines, bacteriophages, and microbiome-altering interventions. ARLG will use funds to maintain centers supporting the network, including a Scientific Leadership Center to provide administrative guidance and oversight; a Clinical Operations Center to provide support for trials and studies; a Laboratory Center to oversee laboratory research and trial specimens; and a Statistics and Data Management Center to assist with study design and analysis.

The renewal support from the NIAID will allow the ARLG to continue its collaborative work to advance science in antibacterial research, and to provide funding opportunities for the next generation of researchers dedicated to addressing this public health threat,” Fowler said in a statement.